← All comparisons
Head-to-head · FAERS comparison

Ustekinumab vs Risankizumab-Rzaa: side effects in FDA adverse event reports

How to read this page. FAERS report counts have no denominator; the comparison is of reporting patterns, not of risk. Signals are screened against each FDA label (badges) but not causally assessed. Not medical advice.

At a glance

UstekinumabRisankizumab-Rzaa
Drug classInterleukin-12 Antagonist, Interleukin-23 AntagonistInterleukin-23 Antagonist
Brand names–Skyrizi
FAERS reports101,62981,276
Serious59%66%
Death outcome5,9502,905
Boxed warningNoNo

Signals both drugs share

ReactionUstekinumabRisankizumab-RzaaLabel screen (A / B)
Ileocaecal resection121 · PRR 118.350 · PRR 45.6Not in label — unassessed / Not in label — unassessed
Ileectomy72 · PRR 55.628 · PRR 23.2Not in label — unassessed / Not in label — unassessed

Labeled signals distinctive to Ustekinumab

Labeled signals distinctive to Risankizumab-Rzaa

Common questions

Which has more reported side effects, Ustekinumab or Risankizumab-Rzaa?

Ustekinumab has 101,629 FAERS reports and Risankizumab-Rzaa 81,276. More reports does not mean more dangerous: volume follows how widely and how long a drug has been used, prescription vs over-the-counter status, and publicity. The seriousness share (59% vs 66%) is a better like-for-like signal of the kind of problems reported.

Which side effects do Ustekinumab and Risankizumab-Rzaa share?

Both drugs carry disproportionality signals for ileocaecal resection, ileectomy. Shared signals often reflect a shared drug class or the condition both are used for.

Is Ustekinumab or Risankizumab-Rzaa safer?

FAERS cannot answer that: it has no denominator and no comparator. Use this page to see which risks are already on each label and which signals are unlabeled, then check the prescribing information and your clinician for your situation.

Sources: openFDA FAERS pair statistics (OpenPV build 2026-09-14), FDA labels via openFDA, openFDA count queries for seriousness and deaths. Pair chosen because it is a commonly searched comparison. Generated 2026-10-08.